Search for content, post, videos

Empros Pharma results published in scientific journal

The company’s study is published in the journal Obesity, and also chosen as “Editor’s Choice” for the November issue.

The aim of Empros Pharma’s study was to evaluate the effect of a novel, oral, modified-release formulation of the lipase inhibitor orlistat and the glucosidase/amylase inhibitor acarbose (denoted EMP16) on relative body weight after 26 weeks compared with placebo.

Conclusions

This trial indicates that orlistat and acarbose can be successfully combined in a modified-release formulation to provide efficacious weight loss with no unexpected safety issues. EMP16 may be a promising candidate among other medications for improved weight management.

Advertisement

Read the article here!

Photo: iStock

Advertisement